Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease

NCT07439887 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Stargardt Disease

Interventions

GENETIC: RTx-021

Sponsor

Ray Therapeutics, Inc.